Latest Insmed Inc (INSM) Headlines
Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma
PR Newswire - Fri Mar 07, 5:19AM CST
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insmed Reports 2013 Fourth Quarter and Full Year Financial Results
Marketwire - Thu Mar 06, 6:45AM CST
Insmed Incorporated (NASDAQ: INSM) today reported financial results for the three and twelve months ended December 31, 2013. The Company will not hold a quarterly conference call to discuss these results given the proximity to the scheduled announcement in late March of top-line results from its phase 2 clinical trial with ARIKAYCE(R) to treat nontuberculous mycobacteria (NTM) lung infections. The Company plans to hold a conference call at that time.
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Sanusi Asks Court to Reinstate Him
by Chuks Okocha, Tobi Soniyi and Linda Eroke - All Africa Global Media - Wed Feb 26, 1:35AM CST
The suspended Governor of the Central Bank of Nigeria (CBN), Mallam Sanusi Lamido Sanusi, has filed another suit at the Federal High Court in Abuja asking for an interlocutory order restraining President Goodluck Jonathan, the Attorney General of the Federation and the Inspector General of Police (IG) from giving effect to his purported suspension from office as the governor of the CBN, pending the determination of his suit.
Interim Data on Insmed's Arikace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:10PM CST
Insmed provided an interim update from the ongoing extension study on Arikace.
Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
Business Wire - Wed Feb 19, 6:00AM CST
Insmed Incorporated (Nasdaq GS:INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, provides an interim update from the Company's CLEAR-110 study, an ongoing, two-year, open-label extension study of once-daily ARIKACE(R), or liposomal amikacin for inhalation, to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients. These data are from 98 patients who have completed the first 12 months (six cycles) of the CLEAR-110 extension study. The data were collected as part of a scheduled data safety monitoring board (DSMB) review of the CLEAR-110 extension study. The data showed that ARIKACE was well tolerated, and there was a sustained improvement from baseline level in Forced Expiratory Volume in One Second (FEV1). These patients also experienced a sustained reduction in density of Pa sputum while on treatment.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 18, 12:31PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Downgrade Alert for Insmed (INSM)
Comtex SmarTrend(R) - Tue Feb 11, 6:59AM CST
Insmed (NASDAQ:INSM) was downgraded from Outperform to Underperform at Wedbush today. The stock closed yesterday at $19.09 on volume of 289,000 shares, below average daily volume of 346,000. Insmed (NASDAQ:INSM) has potential upside of 45.6% based on a current price of $19.11 and analysts' consensus price target of $27.83. Insmed shares have support at the 50-day moving average (MA) of $18.17 and additional support at the 200-day MA of $14.18.
ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria
Marketwire - Mon Feb 10, 7:15AM CST
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion on the Company's application for orphan designation for ARIKACE(R), the Company's liposomal amikacin for inhalation, for the treatment of lung disease caused by nontuberculous mycobacteria (NTM). Orphan drug designation in the European Union (EU) is given to products that are designed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or chronically debilitating.
Insmed Has Returned 20.8% Since SmarTrend Recommendation (INSM)
Comtex SmarTrend(R) - Fri Feb 07, 9:16AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 4 months, Insmed has returned 20.77% as of today's recent price of $18.90.
Insmed to Present at the Leerink Swann Global Healthcare Conference
Marketwire - Tue Feb 04, 7:15AM CST
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that members of the Company's executive management team will be presenting at the Leerink Swann Global Healthcare Conference taking place February 12-13, 2014 at the Waldorf Astoria Hotel in New York City.
Uptrend Call Working As Insmed Stock Rises 33.5% (INSM)
Comtex SmarTrend(R) - Thu Jan 30, 4:51PM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 33.55% as of today's recent price of $20.90.
Insmed Up 33.0% Since SmarTrend Uptrend Call (INSM)
Comtex SmarTrend(R) - Thu Jan 23, 11:00AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 32.97% as of today's recent price of $20.81.
Insmed Shares Up 38.8% Since SmarTrend's Buy Recommendation (INSM)
Comtex SmarTrend(R) - Thu Jan 16, 9:37AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 38.85% as of today's recent price of $21.73.
Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed
PR Newswire - Tue Jan 14, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Insmed Shares Up 24.2% Since SmarTrend's Buy Recommendation (INSM)
Comtex SmarTrend(R) - Thu Jan 09, 9:17AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 24.19% as of today's recent price of $19.43.
Financial Results Releases, Clinical Study Updates, Stock Summaries, and Strategic Agreements - Analyst Notes on Insmed, Medtronic, CR Bard, LabCorp, and Acceleron Pharma
PR Newswire - Fri Mar 07, 5:19AM CST
Today, Analysts Review released its analysts' notes regarding Insmed Incorporated (NASDAQ: INSM), Medtronic, Inc. (NYSE: MDT), CR Bard Inc. (NYSE: BCR), Laboratory Corp. of America Holdings (NYSE: LH), and Acceleron Pharma, Inc. (NASDAQ: XLRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Insmed Reports 2013 Fourth Quarter and Full Year Financial Results
Marketwire - Thu Mar 06, 6:45AM CST
Insmed Incorporated (NASDAQ: INSM) today reported financial results for the three and twelve months ended December 31, 2013. The Company will not hold a quarterly conference call to discuss these results given the proximity to the scheduled announcement in late March of top-line results from its phase 2 clinical trial with ARIKAYCE(R) to treat nontuberculous mycobacteria (NTM) lung infections. The Company plans to hold a conference call at that time.
A Busy Calendar of March Biotech Events
at The Street - Mon Mar 03, 12:13PM CST
Drug approvals, FDA advisory panels and clinical trial results all on tap over the next 30 days.
Sanusi Asks Court to Reinstate Him
by Chuks Okocha, Tobi Soniyi and Linda Eroke - All Africa Global Media - Wed Feb 26, 1:35AM CST
The suspended Governor of the Central Bank of Nigeria (CBN), Mallam Sanusi Lamido Sanusi, has filed another suit at the Federal High Court in Abuja asking for an interlocutory order restraining President Goodluck Jonathan, the Attorney General of the Federation and the Inspector General of Police (IG) from giving effect to his purported suspension from office as the governor of the CBN, pending the determination of his suit.
Interim Data on Insmed's Arikace - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 4:10PM CST
Insmed provided an interim update from the ongoing extension study on Arikace.
Insmed Provides Interim Update from Two-Year, Open-Label Extension Study of ARIKACE to Treat Pseudomonas aeruginosa in Cystic Fibrosis Patients
Business Wire - Wed Feb 19, 6:00AM CST
Insmed Incorporated (Nasdaq GS:INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, provides an interim update from the Company's CLEAR-110 study, an ongoing, two-year, open-label extension study of once-daily ARIKACE(R), or liposomal amikacin for inhalation, to treat Pseudomonas aeruginosa (Pa) in cystic fibrosis (CF) patients. These data are from 98 patients who have completed the first 12 months (six cycles) of the CLEAR-110 extension study. The data were collected as part of a scheduled data safety monitoring board (DSMB) review of the CLEAR-110 extension study. The data showed that ARIKACE was well tolerated, and there was a sustained improvement from baseline level in Forced Expiratory Volume in One Second (FEV1). These patients also experienced a sustained reduction in density of Pa sputum while on treatment.
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 18, 12:31PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Downgrade Alert for Insmed (INSM)
Comtex SmarTrend(R) - Tue Feb 11, 6:59AM CST
Insmed (NASDAQ:INSM) was downgraded from Outperform to Underperform at Wedbush today. The stock closed yesterday at $19.09 on volume of 289,000 shares, below average daily volume of 346,000. Insmed (NASDAQ:INSM) has potential upside of 45.6% based on a current price of $19.11 and analysts' consensus price target of $27.83. Insmed shares have support at the 50-day moving average (MA) of $18.17 and additional support at the 200-day MA of $14.18.
ARIKACE to Receive Orphan Medicinal Product Designation in the European Union to Treat Lung Infections Caused by Nontuberculous Mycobacteria
Marketwire - Mon Feb 10, 7:15AM CST
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has issued a positive opinion on the Company's application for orphan designation for ARIKACE(R), the Company's liposomal amikacin for inhalation, for the treatment of lung disease caused by nontuberculous mycobacteria (NTM). Orphan drug designation in the European Union (EU) is given to products that are designed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or chronically debilitating.
Insmed Has Returned 20.8% Since SmarTrend Recommendation (INSM)
Comtex SmarTrend(R) - Fri Feb 07, 9:16AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 4 months, Insmed has returned 20.77% as of today's recent price of $18.90.
Insmed to Present at the Leerink Swann Global Healthcare Conference
Marketwire - Tue Feb 04, 7:15AM CST
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that members of the Company's executive management team will be presenting at the Leerink Swann Global Healthcare Conference taking place February 12-13, 2014 at the Waldorf Astoria Hotel in New York City.
Uptrend Call Working As Insmed Stock Rises 33.5% (INSM)
Comtex SmarTrend(R) - Thu Jan 30, 4:51PM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 33.55% as of today's recent price of $20.90.
Insmed Up 33.0% Since SmarTrend Uptrend Call (INSM)
Comtex SmarTrend(R) - Thu Jan 23, 11:00AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 32.97% as of today's recent price of $20.81.
Insmed Shares Up 38.8% Since SmarTrend's Buy Recommendation (INSM)
Comtex SmarTrend(R) - Thu Jan 16, 9:37AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 38.85% as of today's recent price of $21.73.
Healthcare Companies Report Petition Submission, Pricing of Follow-On Offerings and Stock Price Movements - Research Report on Johnson & Johnson, GW Pharma, Conatus Pharma, Chelsea, and Insmed
PR Newswire - Tue Jan 14, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.
Insmed Shares Up 24.2% Since SmarTrend's Buy Recommendation (INSM)
Comtex SmarTrend(R) - Thu Jan 09, 9:17AM CST
SmarTrend identified an Uptrend for Insmed (NASDAQ:INSM) on October 18th, 2013 at $15.65. In approximately 3 months, Insmed has returned 24.19% as of today's recent price of $19.43.
